Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 321
- Registration Number
- NCT02117479
Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer
- Conditions
- Stage II Breast CancerStage III Breast Cancer
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2014-04-15
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT02115152
- Locations
- 🇨🇳
Breast Cancer Surgery Department of Guangxi Medical University Cancer Center, Nanning, Guangxi, China
Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- Drug: Capecitabine/cisplatinDrug: CapecitabineDrug: S-1/cisplatinDrug: S-1Drug: Capecitabine/oxaliplatinDrug: 5-fluorouracilDrug: 5-fluorouracil/oxaliplatin
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 111
- Registration Number
- NCT02114359
- Locations
- 🇰🇷
Yeongnam University Medical Center, Daegu, Korea, Republic of
🇰🇷Kyungpook National University Medical Center, Daegu, Korea, Republic of
🇰🇷Inje University Haeundae Paik Hospital, Busan, Korea, Republic of
Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Sanofi
- Registration Number
- NCT02085005
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: Sym004 (9/6 mg/kg)Drug: Sym004 (12 mg/kg)Other: Best Supportive Care (BSC)Drug: Fluorouracil (5-FU)Drug: Capecitabine
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 254
- Registration Number
- NCT02083653
- Locations
- 🇺🇸
Mercy Research, Springfield, Missouri, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States
Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
- Conditions
- Locally Advanced Unresectable Gastric CancerMetastatic Gastric Cancer
- Interventions
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
- Target Recruit Count
- 171
- Registration Number
- NCT02076594
- Locations
- 🇮🇹
Ospedale L. Sacco, Milano, MI, Italy
🇮🇹Osped. Di Circolo Serbelloni-Gorgonzola, Gorgonzola, MI, Italy
🇮🇹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, BG, Italy
Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT02071043
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT02068131
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, China
Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Beijing Chao Yang Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT02043821
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
- Conditions
- BCLC Stage D Adult Hepatocellular CarcinomaRecurrent Extrahepatic Bile Duct CarcinomaLocalized Non-Resectable Adult Liver CarcinomaStage III Childhood Hepatocellular CarcinomaStage IVA Gallbladder CancerAdult CholangiocarcinomaAdvanced Adult Hepatocellular CarcinomaStage IV Childhood Hepatocellular CarcinomaRecurrent Adult Liver CarcinomaStage IIIA Gallbladder Cancer
- Interventions
- Drug: CapecitabineDrug: TrametinibDrug: FluorouracilOther: Laboratory Biomarker AnalysisDrug: Leucovorin Calcium
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT02042443
- Locations
- 🇺🇸
Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States
🇺🇸Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.